Zacks.com Announces That Lon Juricic Highlights the Following Stocks: Kosan Biosciences, Spectranetics Corporation, Given Imaging, and Paradigm Genetics.Business Editors CHICAGO--(BUSINESS WIRE)--Jan. 16, 2004 Get in under the market's radar with a pair of biotech recommendations from Lon Juricic, and let this innovative industry keep you on a profitable course. Read about Kosan Biosciences (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :KOSN), Spectranetics Corporation (NASDAQ:SPNC SPNC South Peel Naturalists' Club (Canada) SPNC Socialist Party of North Carolina SPNC Sales Price Net of total seller paid Concessions (real estate) ), Given Imaging Ltd. (NASDAQ:GIVN), and Paradigm Genetics (NASDAQ:PDGM). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Here are the highlights from the Featured Expert column: Kosan Biosciences (NASDAQ:KOSN) has two lead clinical programs: KOS-862 and 17-AAG. Both compounds are derived from an important class of natural products known as polyketides. By applying its gene engineering technologies to generate proprietary polyketide analogs and by increasing the production yields of polyketides, Kosan has created a pipeline of product candidates for cancer, as well as for infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and other therapeutic areas. Kosan could be a big winner in 2004. Lon Juricic and his team are very excited about the prospects for the company related to its cancer treatment KOS-862, the company's cash position, and the company's 'undiscovered' status. While currently Kosan has coverage from three analysts, the stock is still relatively undiscovered on Wall Street. much longer. Updated Position The Spectranetics Corporation (NASDAQ:SPNC) develops, manufactures, markets and distributes single-use medical devices used in minimally invasive surgical procedures Surgical procedures have long and possibly daunting names. The meaning of many surgical procedure names can often be understood if the name is broken into parts. For example in splenectomy, "ectomy" is a suffix meaning the removal of a part of the body. "Splene-" means spleen. within the cardiovascular system cardiovascular system: see circulatory system. cardiovascular system System of vessels that convey blood to and from tissues throughout the body, bringing nutrients and oxygen and removing wastes and carbon dioxide. , in conjunction with its proprietary excimer laser A gas laser in which a very short electrical pulse excites a mixture containing a halogen such as fluorine and a rare gas such as argon or krypton. It produces a brief, intense pulse of ultraviolet light. system. The stock of Spectranetics was decimated back in early October after the company said the Circulatory System circulatory system, group of organs that transport blood and the substances it carries to and from all parts of the body. The circulatory system can be considered as composed of two parts: the systemic circulation, which serves the body as a whole except for the Devices Advisory Panel of the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. recommended non-approval of its Pre-Market Approval (PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ) supplement for LACI LACI Cardiology 1 A clinical trail–Laser Angioplasty for Critical Ischemia 2 Lipoprotein-associated coagulation inhibitor, aka Tissue factor pathway inhibitor, see there (Laser Angioplasty for Critical Limb Ischemia). LACI will be one of the great growth drivers for the company going forward but even without approval Juricic is still excited about the current valuation of Spectranetics. The market cap on the stock is approximately $100 million, while the company has $12.9 million in cash and equivalents on hand and boasts a $1 million yearly profit. Other stocks in the current portfolio include: Given Imaging Ltd. (NASDAQ:GIVN) developed the Given System, a proprietary wireless imaging system that represents a fundamentally new approach to visual examination of the gastrointestinal tract gastrointestinal tract n. The part of the digestive system consisting of the stomach, small intestine, and large intestine. Gastrointestinal tract . Paradigm Genetics (NASDAQ:PDGM) is industrializing the process of gene function determination for major sectors of the global economy: nutrition, crop production, industrial products, and human health. Read more about the above-mentioned companies, and make sure to get a complete view of Lon Juricic's positions by clicking: http://at.zacks.com/?id=85 About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=87 Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion